

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ASCENTAGE PHARMA GROUP INTERNATIONAL**

### **亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

## **APPOINTMENT OF CHIEF FINANCIAL OFFICER**

The board (the “**Board**”) of directors (the “**Directors**”) of Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”, together with its subsidiaries, the “**Group**”) is pleased to announce it has appointed Mr. Chen Yiqing (“**Mr. Chen**”) as the chief financial officer of the Company with effect from November 29, 2021.

The biographical details of Mr. Chen are set out as follows:

**Mr. Chen Yiqing**, aged 37, prior to joining the Company, Mr. Chen served as the vice-Chief Financial Officer and General Manager of the investor relations and capital development department of Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥(集團)股份有限公司). From June 2021 to September 2021, he served as the deputy general manager of BGI Genomics Co., Ltd (深圳華大基因股份有限公司). From June 2015 to June 2021, he served as the Chief Financial Officer of BGI Genomics Co., Ltd. (深圳華大基因股份有限公司). From September 2014 to May 2015, he served as the Chief Financial Officer of BGI Tech Solutions Co., Ltd. (深圳華大基因科技服務有限公司). From July 2012 to September 2014, he served as the Business Director of the Investment Banking Department of Citi Orient Securities Company Limited (東方花旗證券有限公司). From June 2010 to June 2012, he served as the Deputy Business Director of the Investment Banking Department of Orient Securities Co., Ltd. (東方證券股份有限公司). From September 2006 to June 2010, he served as the senior auditor of the Shanghai branch of Ernst & Young (安永華明會計師事務所上海分所).

Mr. Chen attended Shanghai Jiao Tong University (上海交通大學) from 2002 to 2006 and obtained a bachelor’s degree in Food Science and Engineering. Mr. Chen also attended China Europe International Business School (中歐國際工商學院) and obtained a master’s degree in business administration in August 2016.

Mr. Chen is a Chinese Certified Public Accountant, a fellow of the Chartered Institute of Management Accountants, a Chartered Global Management Accountant, a member of the Association of Chartered Certified Accountants (ACCA), and a member of the ACCA South China Expert Tutorial Group.

The remuneration of Mr. Chen as the chief financial officer of the Company will be determined in accordance with applicable laws, regulations, regulatory requirements and relevant policies of the Company as set up by its remuneration committee, with reference to industry market standards, operations of the Company as well as the merit, qualifications and competence of Mr. Chen.

Save as disclosed above, as at the date of this announcement, Mr. Chen (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any other major appointments and professional qualifications; (v) does not have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (vi) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited; and (vii) has no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warm welcome to Mr. Chen for joining the Company.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, November 29, 2021

*As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director; Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*